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The use of anabolic androgenic steroids (AAS) and associated image and performance enhancing drugs 
(IPEDs) is now a global phenomenon. There is a need to develop evidence to support the development 
of interventions to prevent the commencement of use, to minimise the potential harms or to support 
those in their cessation of use. While the United Kingdom (UK) is no exception to this issue, its public 
health and legislative response to the phenomenon differs to other countries and requires the 
examination of research specific to the UK. Therefore, a scoping review has been conducted to 
examine the recent relevant literature to help inform the development and evaluation of effective 
interventions to reduce the harmful use of IPEDs. 
Methods 
A comprehensive search strategy was developed for multiple bibliographic databases, supported by 
and iterative citation searching process and complimented by expert input from the Anabolic Steroid 
UK Network. Research conducted by or UK academics or within the UK were eligible, if published in 




In total 87 eligible outputs were identified, including 26 review articles, 25 qualitative papers and 24 
quantitative papers. together with small numbers of clinical studies/case reports (6) and 
commentaries/correspondence (6). The most common topics of research were public health, 
treatment and harm reduction (41), followed by studies focusing on epidemiology, sub-groups of 
people using IPEDs and motivations for use (34). The studies illustrated the diverse populations of 
people who use a range of enhancement drugs including concomitant psychoactive drug use. A 
number of papers focused on blood borne viruses and associated issues, while others reported on the 
uptake of needle and syringe programmes. No effectiveness evaluations related to any aspect of 
treatment, harm reduction or other intervention were published during study period.  
Conclusion 
There is a need for the development of effectiveness evaluations of current interventions and any 
future service provision for people using image and performance enhancing drugs. While there have 
been no studies of this nature to date, this review illustrates the rich data that has been gathered 










Image and performance and enhancing drugs (IPEDs) include a wide range of drugs across various 
pharmacological categories. Their common features are the function of their use: the alteration of 
physical performance, or appearance. IPEDs (1) form a subset of human enhancement drugs (HEDs) 
(1-3), and are predominantly those that promote lean muscle mass (e.g., anabolic androgenic 
steroids [AAS], human growth hormone [hGH]) but may also include weight loss products such as 
dinitrophenol or skin tanning injections (e.g., melanotan II). Whilst the use of IPEDs is by no means a 
new phenomenon, until relatively recently attention has been largely restricted to professional/elite 
athletes and bodybuilders. However, IPED use has moved beyond the sporting arena and is now 
commonplace amongst non-elite, recreational trainers within mainstream gymnasia  (1-7). This 
situation is not unique to the United Kingdom (UK) and other high-income countries such as the 
United States of America (USA), Australia and those within Western Europe. Research has identified 
widespread use of IPEDs in countries across the globe (8), including countries in the Middle East (9) 
and South America (10, 11).  
The UK is unique in its response to the use of IPEDs. In the 1990s, on the recommendation of the 
Advisory Council for the Misuse of Drugs, a decision was made not to criminalise the personal 
possession of these drugs, but to focus legislation on manufacture, distribution, and possession with 
intent to supply (12). Subsequently, this principle has been maintained, with adjustments to curtail 
purchasing of AAS from overseas websites but no change to the legality of personal possession of 
AAS and associated IPEDs (13). This approach is supported by a comprehensive network of needle 
and syringe programmes (NSPs) across the UK. Whilst NSPs were originally established in the 1980s 
in response to the HIV threat posed to people who injected heroin, people who inject IPEDs now 
constitute the largest client group for many NSPs in the UK (13-15). The specific situation in the UK 
regarding the legality of AAS possession and the engagement of large numbers of people who use 
AAS, with a network of NSPs provides a unique backdrop to the development of effective 
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interventions for this population. Therefore, in order to identify relevant evidence to support the 
development of these effectiveness evaluations it is necessary to identify collate and review the 
literature that is specific to the UK.    
Unlike the evidence that is specific to the AAS environment in the UK, much of our knowledge in 
relation to the pharmacological effects of IPEDs is generalisable from research around the world and 
includes an increasing body of evidence highlighting physical and psychological harms stemming 
from AAS use. While harms to major organs and systems, in particular the heart and cardiovascular, 
have long been associated with the use of AAS (16), it is only over the last decade that the 
significance of long-term, high-dosage AAS has become apparent (17-19). Alongside the recognised 
physical and mental health impacts, new concerning evidence is emerging in relation to long-term 
use being associated with structural changes to the brain, deviant brain aging, and impaired 
cognition. Recent studies of AAS use and the brain have also concluded that AAS dependence is 
associated with thinner cortex in widespread regions, specifically in prefrontal areas involved in 
inhibitory control and emotional regulation, compared with non-dependent AAS users (20). Recently 
we have also seen greater recognition of prolonged and sometimes irreversible hypogonadism in 
men after long-term use of AAS (21, 22) and how the symptoms of this, including reduced libido (23), 
may lead to continuation or resumption of AAS use. There remains significant debate regarding the 
issue of aggression and violence being associated with AAS use. Recent research has concluded that 
for some, AAS use may contribute to aggression levels (24). Also, while there remains the need to 
elucidate the mechanisms involved (25), an association between aggression and AAS dependence 
has been identified (26).  
While the majority of people who use AAS and associated IPEDs inject at least some of these drugs 
(27, 28),a recent review of blood borne virus (BBV) infection amongst people who use AAS and 
associated IPEDs highlighted the paucity of relevant robust data globally (29). Just nine papers 
published since 2000 were identified, four from the UK and Australia respectively and one from the 
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USA. Whilst several of these studies were focused on AAS use within populations of gay and bisexual 
men, the large-scale UK research studies recruited AAS users from NSPs or directly from gyms. The 
UK study of 2010/11 identified 2% of the 395 participants as HIV positive, similar levels to those seen 
amongst people who inject psychoactive drugs (30). This was supported by further data collection 
and analyses of surveillance data dating back to 1992, using a sample of 1296 people who had 
injected IPEDs. Results indicated that HIV had been present within this population for some time and 
provided an HIV prevalence of 1% for this period (31). As yet we do not know the route of 
transmission of infection and the role that sexual contact and psychoactive drug injection may play. 
Furthermore, we do not know if this pattern of HIV infection amongst people who inject IPEDs is 
mirrored in other countries. Injection site infection and injury is a widely recognised issue. Pain and 
inflammation at injections sites have been identified at significant levels in studies from the UK (32), 
USA (33), Australia (34) and Holland (35). While poor injecting techniques contribute to these 
localised infections, adulterated and contaminated products, an inevitable by-product of the illicit 
market is an ongoing issue on a global scale and overseas (36-39). 
While AAS are the most used IPEDs, polypharmacy is the norm (7, 40). Additional anabolic 
substances, such as human growth hormone (hGH) and a range of new peptide hormones (e.g., 
growth hormone-releasing peptide-6) are commonly used. Drugs to prevent or mitigate side-effects 
(e.g., tamoxifen to counter gynaecomastia), human chorionic gonadotrophin (for the resumption of 
normal testicular function) and a range of weight loss drugs (e.g., ephedrine, dinitrophenol, 
clenbuterol) are also part of the established pharmacopeia. Low-cost production and distribution, 
combined with the increasing sourcing routes via the internet has resulted in substances that were 
once prohibitively expensive now being commonplace (41). Furthermore, the use of other human 
enhancement drugs including melanotan II and sildenafil combined with psychoactive drugs is 
prevalent amongst some cohorts who use IPEDs, sometimes with significant potential for harmful 
interactions with certain drugs (e.g., cocaine) (42).  
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People who use AAS and associated IPEDs are by no means a homogenous group. Recent work has 
highlighted various typologies of user comprised of multiple subgroups with varied characteristics, 
risk behaviours and levels of engagement with support services (43-45). While the focus of much of 
the research has centred on male use of these substances use, women do use IPEDs and in some 
cases use AAS, for those women using AAS the potential harms are more significant and sometimes 
compounded by an added sense of stigma and reluctance to engage with support services or 
healthcare (46). 
The need for evidence to support our understanding of interventions that can reduce the harmful 
use of IPEDs is increasingly recognised (e.g. (47, 48)). As attention from the research community on 
IPEDs has amplified substantially in recent decades (15), the enlarged evidence base may provide 
valuable insights that will support those working to reduce harm amongst people who use IPEDs and 
ensure that approaches are based on a thorough understanding of up to date evidence. The review 
therefore sought to identify and explore evidence that will support the development and evaluation 
of effective interventions to reduce the harmful use of IPEDs. The underpinning research question 
developed by the research team was “how has the academic literature base on the use of IPEDs in 
the UK developed in the past five years and what does it tell us?”. Specifically, we sought to gain 
insight into the characteristics of studies investigating IPED use including: the methods used, topics 
of research, the characteristics of study populations, and key themes within study findings and 
recommendations. We conducted a scoping review of UK literature on the use of IPEDs to map and 
describe extant UK based literature, and in partial fulfilment of the UK National Institute for Health 
Research development grant (NIHR 132730), Image and Performance Enhancing Drugs (IPEDs): 
Assessment of available intelligence and research gaps to inform intervention evaluation’ (47).  
While the international evidence base pertaining to the pharmacological effects of AAS and 
associated IPEDs is largely applicable to the UK, the specific situation in the UK warranted a review of 
the UK published literature over the last five years. It is within this environment that we sought to 
identify the current research landscape to ultimately inform the development of evidence based 
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effective interventions. Therefore, this review looked specifically at the AAS/IPED outputs from UK 
academics/institutions. These results compliment related NIHR research activity comprising 
estimations of the size of the population of people who use AAS, the extent and characteristics of 




A scoping review design was chosen to map and describe what is known about the current status and 
focus of research in relation to IPEDs in the UK. Scoping reviews were first proposed by Arksey and 
O'Malley (49) and have been further advanced by others over the last decade (50-52). More recently, 
Tricco, Lillie (53) defined scoping reviews as “a type of knowledge synthesis, follow a systematic 
approach to map evidence on a topic and identify main concepts, theories, sources, and knowledge 
gaps”. This independent research methodology addresses broader research questions than systematic 
reviews can answer (49-52). Scoping reviews are generally conducted to identify knowledge gaps, 
examine the extent (i.e. size), range (i.e. variety), and nature (i.e. characteristics) of a specific topic, 
summarise the findings of a heterogeneous body of knowledge, and propose agendas for future policy 
and research (49, 52, 54, 55).  
Search Strategy 
Arksey and O'Malley (49) five-stage iterative scoping review methodology was adhered to, namely: 
(1) identifying the essential research question, (2) identifying relevant studies, (3) study selection, (4) 
charting the data, and (5) collecting, summarising, and reporting the results. A search was undertaken 
in January 2021, in Liverpool John Moores University Library catalogues using the following databases: 
Web of Science; MEDLINE; Science Direct; PsycINFO; SPORTDiscus; CINHAL Plus; PubMed; Google 
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Scholar, and Google. Search terms were compiled and agreed by the research team who had extensive 
knowledge and experience of public health, addiction, and IPED research (see Table 1).  
Table 1: Search Terms for image & performance enhancing drug research outputs 2016-2020 






“image and performance enhanc* drug*” OR “performance 





“anabolic androgenic steroid” OR “anabolic–androgenic 
steroid*” OR "anabolic steroid*” OR “Formebolone” OR 
“Methenolone Enantate” OR “Oxymetholone” OR 
“Methandrostenolone” OR “Oxandrolone” OR “Stanozolol” 
OR “Masterolone” OR “Nandrolone” OR “Testosterone 
Enanthate” OR “Testosterone Propionate” OR “Testosterone 
Cypionate” OR “Trenbolone” OR “Boldenone Undecylenate” 






“human growth hormone” OR “somatropin” OR “somatrem”  
“melanotan” OR “bremelanotide” OR “afamelanotide” 
“GHRP*” OR “Growth hormone-releasing peptide” 
“Human chorionic gonadotrophin” OR “hCG” 
Weight Loss “Clenbuterol” OR “Sibutramine” OR “Rimonabant” OR 
“Dinitrophenol” OR “DNP” 
Doping Control “Doping” OR “anti-doping” 
 
Oils, Fillers 
“Paraffin oil injection” OR “site enhancement oil injection” OR 
“muscle fillers” OR “body fillers” OR “polyvitamin injection” 
OR 
“synthol injection” 
SARMs “SARMs” OR “tamoxifen” OR “raloxifene” OR “lasofoxifene” 
OR “bazedoxifene” OR “clomiphene citrate” 
SERMs “SERMs” OR “Ostarine” OR “Ligandrol” OR “Testolone” OR 
“Andarine” 
United Kingdom “United Kingdom” OR “UK” or “U.K.” OR “England” OR 





The initial search identified 4,882 articles based on the search terms outlined above (see Table 1), 
References were imported to Endnote® citation manager where they were organised. An initial 
examination of the articles indicated the possibility of many irrelevant articles. Duplicates were 
removed (n=1,279) followed by title and abstract screening of the remainder (n=3,461), where 
inclusion and exclusion criteria were applied to all citations. Studies included were: all published 
empirical research including articles in peer-reviewed journals and book chapters; and grey literature 
such as national policy reports and documents, needs assessments, service evaluations, and locally 
commissioned research. Date range was restricted to between January 1st 2016 and December 31st 
2020 to capture current, relevant literature to inform the development and evaluation of effective 
interventions to reduce harmful IPED use, and studies conducted by UK academics or those with a UK 
focus due to the unique situation in the UK relating to legislation and NSP provision. Academic theses, 
animal models, and in-vitro studies were excluded. A total of 77 records were identified at this stage 
of the search (see Figure 1). Papers were subsequently reviewed and screened to ensure those 
included met the inclusion criteria and discrepancies resolved (54). Manual searching of the reference 
lists of the 77 records was conducted to identify any relevant literature that was not captured in the 
initial search. Subsequently, consultation with academics and healthcare professionals with relevant 
expertise (accessed through the Academic Steroid UK Network) was conducted to ensure all relevant 
literature was included, as recommended by Daudt, van Mossel (54). This was a valuable step in the 
process as the depth and breadth of knowledge each expert brought strengthened the review and 
consequently, the richness of the findings. A final number of 87 sources were included in the review 
(see Figure 1). 
Figure 1 Flow chart of the search strategy used to identify image & performance enhancing drug 




Data extraction and charting 
Data were extracted to form a dataset which included all author names and institutions, year of 
publication, aim and method, population, key findings, implications for policy and practice, and 
identified research gaps in each source.  
Results 
Table 2 provides a detailed overview of UK academic publications on the use of anabolic androgenic 
steroids and IPEDs, presenting an overview of this research to illustrate its volume and main 
characteristics, together with summaries of key findings.   
Table 2 Charted Records of United Kingdom publications on anabolic androgenic steroids and 
associated IPED use (2016-2020) 
Profile of studies reviewed 
The final sample of 87 records present a range of methodologies and foci on AAS and other IPEDs 
within the UK. The majority of evidence was gleaned from the review of 69 journal articles and 
supplemented by 12 relevant academic book chapters and six public health reports. There is no 
discernible trend in the volume, methodologies used or focus of research outputs over the five-year 
period. Apart from 2019, the number of outputs per year ranged between 12 and 17 publications. The 
high number of outputs in 2019 (29) can be explained by the inclusion of 8 chapters from one book 
on the use of human enhancement drugs (1). These records are comprised of a variety of 
methodologies and approaches including qualitative, quantitative and review. In a small minority of 
cases several methods were reported within the research output, however in all cases there was a 
clear predominant method applied. For example, the book chapter ‘The supply of image and 
performance enhancing drugs (IPED) to local non-elite users in England (56), forensic analysis of a 
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small number IPEDs was used to support the findings of two qualitative studies and was therefore 
recorded as a qualitative paper. .  Figure 2 illustrates these methodologies in an aggregated form. The 
26 review articles (including systematic, scoping, and non-specific reviews) account for the largest 
proportion of outputs(30%), followed by 25 predominantly qualitative (29%), 24 quantitative papers 
(27%) with 6 (7%) commentary papers and clinical case studies respectively. 
Figure 2: Methodologies of image & performance enhancing drug research outputs 2016-2020 
Table 2 also includes the main topics of each output. It is important to note that while the category 
of sport/doping control is included, outputs were excluded if this was the sole area of focus. Outputs 
may be attributed to two are more categories. Figure 3 summarises these categories within the year 
of publication. The most common topic of research, included in 41 academic outputs, was public 
health/care (including harm reduction and treatment). This was consistent across each year apart 
from 2018 when epidemiology was the major category, this being the second most common topic 
overall (34).  
Figure 3: Focus of image & performance enhancing drugs research outputs 2016 - 2020 
Key findings 
The UK research from the last 5-years provided a broad spectrum of evidence related to various 
facets of IPED use, from across the full extent of the UK. An indication of the diversity of drugs used 
is provided, together with specific implications. The vast majority of the work was in relation to the 
use of AAS includingone paper looking at the concomitant use of stimulants (42)Four papers 
focusing solely on the use of weight loss drugs (57-60), two papers examining the use of the skin 
tanning drug melanotan (61, 62), two academic outputs describing the emerging use of the 
respective peptide hormones metformin and CJC-1295  (63, 64), and one article examining the use 
of synthol (a site enhancement oil) (65). One paper focused specifically onthose solely taking oral 
AAS and associated drugs (66), two papers examined the relationshipbetween supplements IPED use 
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(67, 68), whilethe role of concomitant psychoactive drugs was emphasised as a cause for concern in 
one paper (7). Six outputs provided accounts of the ease of availability and affordability of drugs 
within a dynamic IPED market (56, 69-73), with the internet playing an important role with a 
significant market crossover with other drug using populations (74-77).  
Research focused on epidemiology, sub-groups, and motives, indicates a complex landscape of 
diverse sub-populations of IPED users, going beyond the stereotypical young male AAS user. 
Different populations and practices were identified with specific practices and risks. Significant sub-
groups included women using a range of substances (78-82) and older men using AAS (28). While 
research that only focused on elite sport and doping control was excluded, sport clearly plays a 
significant role in the use of IPEDs (83) and remains a public policy concern (84). IPED use was also 
associated with specific occupations as diverse as those in the military to those engaged in dance 
(85, 86).  The majority of the literature in this review examined the use of AAS, in particular the use 
of AAS by men. Only four papers solely  focused on the use of IPEDs by women (57, 64, 78, 81). 
This literature also provides an improved understanding of some of the motives for commencement 
of use or abstinence, in particular those related to self-esteem, body image and masculinity (87-96). 
The continuation or resumption of AAS use driven by symptoms of hypogonadism (97-100) was a 
significant finding, together with wider issues related to sexual health (101). Harms associated with 
IPED use were commonly described (18, 19, 102, 103), together with the risk environment (6) and 
efforts by individuals to mitigate these adverse consequences (104). 
Common features within studies centred on public health, treatment, and harm reduction included 
the increasing number of AAS users engaging with NSPs (28, 105, 106) and barriers to service 
engagement including a lack of confidence in practitioners’ knowledge, perceived stigma. A failure to 
recognise the beneficial effects of AAS was identified together with an overemphasis of the harms 
(107-110), while the need for non-judgemental specialised services was emphasised  (111-119). A 
greater understanding of the need for a multi-layered approach to preventing both IPED use in 
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general, and harmful use in particular, was emphasised (91, 120, 121). The need for an 
understanding of the culture as well as the behaviours of people who use IPEDs was deemed 
essential, together with an appreciation that IPEDs may have potential benefits to the user (58, 108, 
110). 
Another recurring theme within this literature was the need for health practitioners to demonstrate 
both a non-judgemental attitude and have a demonstrable level of knowledge of both IPEDs and 
how they are used. This was considered a prerequisite if the current barriers to service engagement 
are to be overcome (110). Practitioners must have an appreciation of the complex relationship 
between AAS use and body image (96) and an understanding that there is a perceived normalisation 
of IPED use within some social groups, with concepts around masculinity and muscularity being 
highly influential on decisions to use IPEDs (91). While the majority of the literature referred to 
practitioners in general, the potential for an increased role for both social workers (115) and 
endocrinologists (116) was highlighted. 
Various aspects of a potential continuum of care and support were also discussed. These ranged 
from prevention activities within a generic health promotion approach, recognising the complex 
factors that make children, youth and adults vulnerable to IPEDs (42, 120, 121), through to the need 
for relapse prevention to divert former AAS users from a focus on their body as their major source of 
self-esteem (94). However, the main area of discussion related to existing and potential harm 
reduction interventions and services (7, 15, 111). In addition to the expansion of innovative 
development and activity within NSPs (107, 122), other venues and modes of engagement to 
promote sexual health (101) and ensure non-stigmatising environments were called for (28, 29, 123, 
124). There were also calls for the implementation of effective assertive outreach (125) and the 




As part of service provision there were also calls for comprehensive testing including physiological 
indicators of harm (112) together with testing for BBVs (126) and psychosocial support regarding 
body image. Such testing for BBVs could draw upon the improved understanding of injecting beliefs 
and behaviours (101), including BBV risks (25, 27, 102-107), evident in the review. Information of 
nutrition and exercise (113), building self-esteem (97), psychological services to address dependence 
and muscle dysmorphia (82, 97), and other body image vulnerabilities (59) were also considered 
necessary. There were consistent findings regarding the need for practitioners to have an 
understanding of the diverse populations of people who use IPEDS (45), the episodic nature of use 
(74), polydrug use (7), those who do not inject (66) and those using drugs other than AAS (58, 60, 
127). An understanding of the market was considered necessary in order to provide credible health 
related information on risks of active ingredients and the quality products obtained through the 
illicit market (64). 
Discussion 
The  diversity of UK published research between 2016 and 2020 reflects a growing scientific and 
academic interest in this phenomenon and underpins the complex issues related to the use of 
available IPEDs. They also indicate the multidisciplinary response that is required if, as researchers, 
practitioners, policy makers, and all importantly, people who use these drugs, are going to synergise 
and work collaboratively to raise awareness increase our understanding and ultimately reduce the 
harms associated with use. The research findings, together with the stated implications for 
policymakers, practitioners and the research community illustrate the broad spectrum of 
opportunities to reduce harm, including prevention, diversion, treatment, cessation support and 
policies that directly affect the illicit market. However, notable by their absence and as highlighted 
within many of the publications is the lack of robust effectiveness of evaluations in relation to 
interventions focused on the use of IPEDs. While the focus of this paper is on recently published UK 
research, due to the unique position we are in, in relation to legislation and needle and syringe 
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provision, it is worth noting that this dearth of intervention effectiveness evidence is replicated 
around the globe. 
Findings also underscore the need for future efforts to develop and evaluate interventions should 
see the involvement of people who use IPEDs as an essential component during all stages of the 
research process. For example, many included records emphasised that interventions should 
encompass peer support groups and educators (113, 125), and a client-centred approach (79, 106). 
Thus, there was a recurring theme within the UK literature of the recognition of the need to 
effectively engage with the communities of people who use IPEDs. It is a widely held belief that the 
required interventions and the research that is needed to test and evaluate them can only be 
achieved with the participation of those who use IPEDs. This belief is supported not only by the IPED-
specific literature reviewed here, but also by the broader literature relevant to the development and 
evaluation of interventions aimed at enhancing or protecting physical and psychological health. 
Often referred to as patient and public involvement (PPI), research funders now frequently endorse 
and sometimes obligate PPI during all stages of health and social care research (129, 130). 
Incorporating PPI can benefit research by promoting recruitment (131), which can enhance its 
validity and reduce costs (132). Moreover, the efficacy of PPI is greatest when those with lived 
experience of the behaviour/condition being studied are represented as research partners, 
supporting the benefits of harnessing knowledge from such experience-based experts alongside that 
of scientists and professionals when designing, delivering, and disseminating research (133). The 
importance of involving those with lived experience of IPED use in research and in developing and 
evaluating harm reduction interventions for IPED use is perhaps even more important than in other 
fields given evidence demonstrating a lack of trust in healthcare professionals when it comes to IPED 
use (134, 135, 136).  
The research literature provided a wealth of far-reaching recommendations for future research. It is 
essential that researchers engage and collaborate with the communities of people who use IPEDs to 
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better understand the patterns of drug-use behaviours, motives and associated risks (28). Future 
research should focus on delivery of holistic healthcare and early intervention for those attending 
NSPs and outreach services (42). However, harm reduction should look beyond NSPs to meet the 
needs of those who do not inject (66). 
While the evidence base related to harms stemming from AAS use has developed over the last 5 
years, there needs to be a continued focus on specific adverse effects for the full range of IPEDs (18, 
19, 65, 117, 123), so that policy makers have a comprehensive understanding of the drivers and 
motives for use and cessation,  and the associated harms for AAS (6, 79, 91, 114, 117, 124) and other 
IPEDs (15, 57-61, 64, 68, 73, 104, 122, 128). We should also develop the evidence and increase our 
understanding of the issues associated with the diverse populations that use IPEDs (95, 105). More 
specifically, research should focus on those people using IPEDs who may be particularly vulnerable 
(76), including women (78, 81), those in prison (117), those with specific occupations and those 
engaging in pertinent activities such as sport (67, 83, 85, 86, 90, 93).  
Motives for commencement, continuation, and potential cessation of IPED use should also receive 
continued research attention (92, 98, 120). Key examples identified for further attention include 
body image (96, 97, 129), muscle dysmorphia (94), muscularity (82), masculinity (87, 130), and 
hypogonadism (99, 113, 115). Research findings indicate a combination of routinely available data, 
survey data and other novel data collection methods should be employed (95), including online 
methodologies to gain a better understanding of the prevalence of use and associated behaviours 
(15, 45, 64, 74, 116, 127). Research is also needed into the clinical treatment of adverse effects (102) 
and how stigma and barriers within generic health services may be effectively addressed (112). This 
is especially pertinent in relation BBV services (28, 31, 119, 126, 131, 132) and sexual health services 
(31), including men who have sex with men and women who have sex with women (101). We also 
need to gain a better understanding of the supply and distribution of IPED, the role of the internet, 
potential for a more regulated market and the harms caused by the illicit market (6, 7, 15, 63, 69, 73-
18 
 
75). The overarching them in relation to identified research gaps and recommended focus of 
attention is the evaluation of interventions to identify cost-effective demand reduction and harm 
reduction solutions (104, 105, 107, 111, 128). Further attention is warranted by policymakers and 
public health surveillance systems to track and monitor this emerging and increasingly mainstream 
form of body modification and consumerism of IPED pharmaceuticals.  
Conclusion 
The UK IPED research community has been highly active over the last five years. This review 
evidences a wealth of data relating to people who use IPEDs, including their practices and associated 
harms. However, where interventions are a focus of the research, findings tend to be descriptive and 
their remains a paucity of effectiveness studies. The literature highlights the need for meaningful 
involvement of people with lived experience, reinforcing the principles of co-production in the 
development of future intervention evaluations to reduce the harms associated with this form of 
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Table 2 Charted Records of United Kingdom publications on anabolic androgenic steroids and 
associated IPED use (2016-2020) 
 
 
First Author; Year; 
Title. 
 
































Use with Stimulant 
Polypharmacy. 
 












AIM: To explore 
polydrug use in 
male AAS users. 









data analysis of 










more likely to 
report 
concurrent use 
of AAS and 
stimulants 
than those 








and AAS were 


















efforts should be 
targeted at the 
general 






Drug education at 
schools should 






efforts should be 





























drugs use in active 
military personnel 





AIM: to scrutinize 
the literature on 
the prevalence 
and motivations 












▪ AAS and weight-
loss IPEDs most 
commonly used. 
▪ Primary reason 
for AAS use was 
for image 
enhancement. 
▪ Second reasons 
for IPED use were 
to have the ability 
to work through 
physical and 
emotional 
demands of active 
duty. 
A policy shift to 
address an 
“acceptable” 
culture of IPED 








of the military 
service is 
needed. 








reason for IPED 
use and how 
they access 















▪ Those most likely 




such as the NHS 
by reducing 
complications 









whether it is 
pre-, during, or 
post-military 
service. 





















 AIM: To explore 


















▪ The availability 
and accessibility 
via the internet of 
‘raw’ powder 
supplies from 
China has resulted 
in changes to the 







▪ The study 
highlights how 
homebrewing may 
impact quality of 
end product at the 
gym-level. 
▪ Study found that 
different steroid 
brands have come 
from the same lab 






supply will likely 
impact policy in 
the future. 



















Abuse in the 
United Kingdom: 










Whalley, B. J. 
Schifano, F. 
Baker, J. S. 
AIM: Review 
current AAS 
use/abuse in the 
UK. 
METHOD: Review 
- ▪ AAS users 
predominantly 






▪ Most UK AAS 
users initiate use 













some have been 








target those most 






to be considered. 
 
Individuals within 
the AAS using 
community 





























AIM: To review 












an early warning 
system to monitor 
enhanced 




















































diffusion of drug 































How the love of 
muscle can break a 

















Enright, K. J. 
Lane, K. E. 
McVeigh, J. 
Stewart, C. E. 
Davies, I. G. 
AIM: To highlight 
the mechanisms 
by which AAS 
exert their 
hypertrophic 
effects on skeletal 
muscle; to explore 
the impact of AAS 




to explore the 





- ▪ Chronic AAS use 
effects 
metabolism thus 
increasing the risk 
of CVD. 
▪ Growing 
prevalence of AAS 
use will intensify 
current rates of 
CVD. 
▪ Chronic AAS use 






▪ These health 










manage AAS and 
AAS-related 
polypharmacy, 
and guidance on 




is required on 
long-term AAS 
use effects on 
markers of 
metabolic 

























feminine: A single 










AIM: To highlight 
the motivations 
for and methods 
of female AAS 













▪ The female 
bodybuilder is 
hyper-conforming 
to cultural norms 
through the over-
identification of a 
hyper-idealised 






AAS is strongly 
associated with 
the desire for 
aesthetic appeal. 
▪ Both long- and 
short-term 
motivations for 
AAS use are 
grounded in a 





advising users of 
possible adverse 





to gain an 
understanding 
of motivations 
for females to 



























with hepatitis C 
and HIV testing 
uptake among 
men who inject 
image and 
performance 


















AIM: To examine 








Data Analysis of 










▪ 2/3rds of IPED 
injectors had 
never been tested 
for HCV or HIV. 





sexual risk.  





to AAS use. 
▪ Uptake or offer 
of testing not 
reported by 50% 
of participants, 
who had been to a 
health service. 




BBV testing along 
with metabolic 
and physiological 





clinics and IPED 
workers at NSPs 







should focus on 
barriers to 
uptake of BBV 
testing among 




















barriers to health 
care access 
amongst people 
using image and 
performance 
enhancing drugs in 













AIM: To verify 
barriers and 
facilitators people 
injecting AAS and 














▪ AAS users felt 
motivating factors 




▪ Majority of AAS 
users minimised 
the health risks 
even though they 
experienced 
adverse effects. 
▪ All participants 
concerned re lack 
of evidence-based 
information for 
both AAS users 
and HCPs.  
▪ Most AAS users 
reluctant to 
disclose use to 
HCPs or seek 
healthcare due to 
fear of 
judgement/stigma. 







by AAS users as it 
was deemed more 
accessible.  
 
It is recommenced 














health and social 




















advised to adopt 




local health and 
social care 
services available 


















































use among men 
who have sex with 
men and women 
who have sex with 







Brett, C. E. 
Porcellato, L. 
A. 
Hope, V. D. 
AIM: To examine 
the scope of IPED 
use among 
MSM and WSW in 
the UK; and to 
investigate the 
factors associated 









▪ 1 in 25 MSM & 
WSW used IPEDs 
in the previous 
year. 
▪ Recent IPED use 
associated with 
psychoactive drug 
use and STI 
diagnoses. 





with life as 
reasons for IPED 
use. 
▪ MSM IPED use 
was associated 
with lower sexual 
self-efficacy.  





chemsex in the 
UK. 
▪ WSW who use 
IPEDs were more 
likely to have 
attended a GUM 
clinic than non-
IPED using WSW 
indicating a 
significant area for 
IPED HR provision 
for WSW. 
Not Discussed GUM clinic 
significant area 






support for body 
dissatisfaction 
and satisfaction 





support for IPED 
relates issues 
such as historical 











use and body 
dissatisfaction 
and satisfaction. 
with life among 
MSM & WSW. 
 
An investigation 
is required to 
confirm if there 






























Faculty of Health 

















 ▪ HR efforts are 
reduced and risks 
are increased for 
individuals who 
use these 
substances due to 
restrictive anti-
doping policies. 
▪ Less restrictions 
may promote 
more HR work but 
social, economic, 
and policy risks 
may remain. 
▪ People who use 
IPEDs in both the 
UK and Sweden 
respond to 
prohibitive 
measures by going 
to an online 
environment 
where discussions 
are centred on HR 
A policy shift away 
from policing and 










clinic which offers 
a wide range of 
services such as 
bloodwork, 
Harm reduction 
services with a 
wide range of 





to assess the 
effectiveness of 
HR strategies as 
well as the 
impact of online 
communities in 
promoting HR 





































AIM: To ascertain 
the types of 
support needed 









▪ AAS users 
expressed a desire 




use; to see more 
evidence-based 
research; and 
were willing to pay 
for healthcare 
services. 
▪ Less than half of 
the participants in 
the UK had 
accessed NSPs. 
▪ Participants felt 
that focusing on 
cessation of use 
was unrealistic 













evidence of a 
more personalised 
approach to AAS 














































need for more 
human-based 
scientific studies 







impact of low 
testosterone on 







for use is 





course of the 
individual. 
⚫ 














University of Wales 
Trinity Saint David, 
West Wales, UK. 
Price, C. AIM: To examine 
the extent of low 
self-esteem in 
men in the 
weightlifting 
community; to 






users; and to 
explore the 
motivations 
behind initial use, 










users in the 
UK. 
▪ Low self-esteem 
identified as a risk 
factor for AAS use 
but Improved self-














cessation as there 
was no longer a 
need for AAS. 
▪ Settling down 
with a partner was 
another motive for 
cessation. 
DSM-IV needs to 
consider the lack 




























is required to 
examine the 
role of body 

















whether MD is a 
precursor or 





































































▪ Motivations for 
AAS use were for 
cosmetic reasons, 













of reluctance to 
seek professional 
care. 
▪ Four main 
themes: a belief 
that GPs and 


























































Van Hout, M.C. 
McVeigh, J. 
AIM: To provide 
















use. 4 male 
and 1 female 
interview. 









because of weight 
loss. 






hives, and an 
irregular 
menstrual cycle. 




even though many 
experienced 
anxiety over these 
effects. 
DNP use needs to 
be considered as 
part of a wider 
health agenda.  






on the harmful 
effects of DNP 
and the ease of 










▪ Many women 
searched for 
advice from online 
forums. 
▪ Females trusted 
the information on 
the forum even 
though it is mainly 
aimed at males 
and women often 
faced disapproval 
and stigma. 
▪ DNP use among 
women was 
considered novice 
use, whilst men 
were seen as 
experts 




Oh take some 





































▪ The role of 
muscularity was 
central to a form 
of aesthetic and 
bodily capital. 































Not Discussed Future research 
should focus on 
encompassing 

































Padilha, M. C. 
Chagas, S. V. 
Baker, J. S. 
Mullen, C. 
Vieira Neto, L. 
Aquino Neto, 
F. R. 










symptoms, and a 
suicide attempt 
resulted in a male 
following 
withdrawal 
symptoms of AAS 
use. 














subsequent use of 
AAS. 
Not Discussed The risk of drug 
interactions 
between AAS and 
Fluoxetine 
should be closely 
monitored given 


























carcinoma in body 
builders; an 








Wales, and Public 






















revealed a liver 
lesion. Ceased AAS 
use 18 months 












epigastric pain.  
Several liver 
lesions with 
bleeding into the 
lesion 
in the left liver 
were observed 
following imaging. 




attributed to AAS 
use. Surgical 
removal of mass 
on liver. 3-month 
review showed no 
recurrence which 
coincided with 













indicate a need 
for AAS user 
communities and 
GPs to be aware 
of the possible 























McVeigh, J. METHOD: Review  ▪ Increased socio-
cultural values in 
the Western world 
are centred on 
bronzed, tanned 





















as well as drug 





be included in 
clinical evaluation 
It is critical that 



















related to the 
introduction of 
use, continued 



















and peer group 
practices and 











is essential to 
identify drivers 
of use and 
relevant 
practices. 








users (AAS): are 
non-injecting 












AIM: To explore 
patterns of AAS 
use and to 
provides unique 

















▪ The majority of 
these AAS users 
reported using 










unlikely to engage 
with NSPs which 
limits their access 
to harm reduction 
and medical 
advice. 


















people who use 





is needed to 
explore why 
people engage 
in oral-only use 







Given that NSPs 
are the most 
common way of 
delivering 
services and 
advice to people 
who use AAS, 




oral use only 
and find ways to 









 AIM: To provide a 
snapshot of the 
nature of IPEDs 
that are being 
 ▪ To address this 
growing issue, it is 
important that a 
multi-agency, 
strategic approach 


























used, where they 
come from and 
who takes them. 
METHOD: Review 
tackle the multiple 
influences for IPED 
use.  




and not just in 
sport. 
▪ The research 
highlights the 
growing public 
health issue of 
IPEDs based on 
copmlex 
influences such as 
media outlets 













to address the 
issue of IPED use. 
important tool 
for encouraging 
clean sport, and 
it should be 
extended to 
minimise the use 




both on society 





use of IPEDs 
specifically 
whether the 
primary driver is 
sport or image 
is warranted. 










for harm reduction 
interventions and 











AIM: To provide 
an in-depth 
account of the use 























▪ Two main 
themes emerged: 
1. Intersection of 
substance use: 
polydrug-using 
repertoires; and  
2. Intersection of 
drug markets: the 
gym as a trading 
bazaar. 
▪ Individuals who 








▪ IPED use and 
supply were found 





▪ IPED use was 
actively supported 
and facilitated by 
the gym and its 
staff members. 
Punitive drug 
policy reform that 
seeks to minimise 
IPED markets 
must consider the 
possibility of social 
supply being 
displaced in 






of IPED users can 
result from 
harsher drug laws.  
 










































(IPED) use within 
the UK, social 







AIM: To explore 
the perspectives 
of steroid users 
regarding the 
social impact of 





24 IPED users ▪ Four main 
themes emerged: 
(1) Culture of 
Steroid Abuse, (2) 
Supply and 
Demand,  




























users on AAS use: 
Negative effects, 
‘code of silence’, 
and implications 








AIM: To offer an 
account of AAS 
users' perception 
of the negative 










AAS users.  
▪ The substance 
reaction and range 
of negative 
experiences varies. 
▪ Medical advice is 
very rarely, if ever 
sought. 
▪ AAS users are a 
hard-to-reach 
population as they 
are unwilling to 
disclose their use 
and negative 
effects to others. 










can be informed. 
Future research 
is needed to 
understand the 
dynamics of 
culture and how 

























University of New 
England (Australia). 







METHOD: Review  ▪ The overstating 
of negative effects 
of steroids has 





▪ A more 
evidence-based 
approach to AAS 
use, free of 
morality and 
sensationalism, 
and based on 
clinical studies can 
mitigate harms. 
▪ The majority of 




others, or die 
because of their 
use. 
Policymakers and 
the public should 
not focus on 
isolated cases of 
harm or tragedy 






reducing harms is 
crucial for 



































to the Editor 
 ▪ As a result of 
AAS abuse, men 
risk reducing their 
probability 
becoming infertile.  
▪ The use of AAS 
and resulting 
negative effects 












Efforts to inform 
doctors and AAS 




fitness and their 




















One size does not 
fit all.  
 













(BBV) in research 
on, and services 
for, people who 





 Underwood (2019) 
voices the 
frustration of AAS 
and other IPED 
users who 
consider BBV as a 
distraction from 
their genuine 
concerns and not a 
significant issue.  
Underwood (2019) 
relays that these 
individuals believe 
themselves to be 
experts of their 




is not an accurate 
representation of 




the findings of 
research specific 
to this population.  
 In the UK 
evidence of BBVs 
among AAS users 
was reported in 
2013.  
The findings of this 
research are 
robust (Hope et al. 







hepatitis C as a 
significant 
concern. (Hope et 
al. 2016).  
Not Discussed Not Discussed Researchers 
should ensure 
that they do not 
inadvertently 























AIM: To explore 
the contemporary 
importance 
attached to both 
attaining and 
maintaining both 
elements of a 
Male AAS 






▪ The authors view 
the role of AAS in 
facilitating bodily 




cultural norms and 
values. 


































Infections and risk 
among people who 
use image and 
performance 







Iversen, J. AIM: To review 
what is known 
about the 
prevalence and 
range of both viral 
and bacterial 
infections among 
those who inject 
and use IPEDs; to 
examine what is 
known about the 
range and extent 





 ▪ The injection of 









hepatitis B and 
hepatitis C).  
▪ Early diagnosis 






▪ The data 
indicates that 
people using IPEDs 
may have an 
elevated risk of 
acquiring 
infections sexually 
when compared to 
the overall general 
population 
The provision of 
and access to 
NSPs, sexual 
health services, 





as blood testing 
services are 
required for the 
reduction of 











those who test 
positive is crucial.  
Healthcare 
professionals 
need to be 
educated on IPED 





















gay and bisexual 


















between users and 
healthcare 
professionals. 
Waring, S.W. AIM: To ascertain 








effects and need 











included: fear of 
being judged, 
perceived lack of 
AAS knowledge 
among GPs, and 





▪ Most GPs would 
not provide blood 
tests for people 
who used IPEDs 
and did not feel 
confident 
Not Discussed Barriers to 
healthcare 
experienced by 
AAS users’ needs 
to be addressed 

























users; 2) Doctors. 
interpreting 
results. 




"Yay, Another Lady 
Starting a Log!": 
Women's Fitness 
Doping and the 
Gendered Space of 
an Online Doping 
Forum. 
 
Faculty of Health 
Sciences and Sport, 
University of 
Stirling, Scotland. 





female IPED use 
and how fitness 
doping can be 
understood in 
terms of gender 
and spatiality, and 
what implications 














▪ Three themes 
emerged: 
Motivations for 




a Gendered Space 
and Practice.   
▪ Even though the 
forum offers a 
platform for 
women to express 
their own specific 
experiences, the 














practice (CofP)  
▪ Women seeking 







Not Discussed Not Discussed Future research 

























Literature Review.  
 





Parrish, M. AIM: To provide 
an overview of 
the physical and 
psychological 
harms associated 




use; to identify 
the risks of AAS 
use to young 









 ▪ Social workers 
should advise AAS 
users and families 
of behavioural 
changes following 
AAS use that may 
result in 
aggression. 
▪ Social workers 
awareness of AAS 
patterns of use is 







▪ Knowledge of 
the legal status of 




▪ Risk assessments 
by social workers 
must be balanced 
and not focus on 
the so-called ‘roid-
rage’ view held by 
the public. 
Not Discussed Social workers 
are required to 
have sufficient 
expertise on the 
complexities of 









partners of AAS 







to young people 
at risk of AAS 











Support for people 




Review into what 
they want and 
what they Access.  
 










AIM: To explore 
and identify the 










 ▪ How to inject, 
effectiveness of 
substances, 
dosages, and side 
effects of AAS use 
were the type of 
information AAS 
users seek.  
▪ Support was 









Not Discussed  Support should 
be tailored to the 





sensitive to AAS 
users’ 
perceptions their 
use and the 
related stigma of 
being associated 
with other IDUs 
to facilitate 
effective 
engagement.   
It is pertinent 











of AAS users 







AAS users.  
⚫ 






















AIM: To focus on 
the extent to 
which MD may 
precipitate or 
perpetuate the 
















▪ MD may force 
vulnerable people 
to initiate a AAS 
use. 
▪ There were no 
variations in MD 
symptoms 
recorded between 
AAS users with 
different lengths 
of AAS exposure. 
▪ The study 
indicates that MD 
could influence 
both the initiation 
and maintenance 
of AAS use. 








may be effective 












to engage in 
weight-resistance 























The (online) supply 















of the nature and 
dynamics of the 
trade of 
enhancement 




online and offline 
settings 
 ▪ This chapter 
illustrates how the 
supply of illicit 
medicines is 
entrenched in 
global variations in 
IPRS, the blurred 





global free market 
and transnational 
trade relations. 
▪ There is a clear 
inextricable link 
between online 
and offline trade. 
▪ The global ease 





expansion in trade 
and opportunities. 






illicit medicines.  
Not Discussed Not Discussed Not Discussed 
⚫ 





























AIM: To estimate 

















NSPs is common. 



















▪ Significant need 



























































One size does not 
fit all: Tackling the 
issue of weight-









AIM: To argue 




 ▪ A ‘one size fits 
all’ model for 
weight-loss drug 
use harm 
reduction may be 
ineffective. 
There is no 
‘typical’ user, and 
a one size fits all 
harm reduction 





are not based on 
a user typology 
but focus on 
vulnerable users 


















































erection lasting 22 
hours. 
▪ Attempted to 





aspiration of blood 
from the corpa 
cavernosa carried 
out. 
▪ Patient did not 
know what dosage 
was in each phial. 
▪ Patient was 
unaware of side-
effects, labelling 
did not provide 
this information. 





























Centre for Clinical 
& Health Research 

















AIM: To explore 
the diffusion of EA 
in fitness settings 
in the United 
Kingdom, Italy, 
Netherlands, 






esteem and the 









present in fitness 
settings in the 
research. 




esteem, and the 





▪ Fitness goals are 
influenced by a 
person’s 
perception of their 
reflection in the 
mirror, or the 
number of “likes” 












address this at 
risk-population. 
as well as the 
need 





















of the self, both 



















than for wellbeing, 
or a hedonistic 
pursuit of pleasure 
is recommended. 








(IPED) to local non-












Salinas, M. AIM: Review of 
two research 
studies on IPED 
supply. 
METHOD: Review 
of 2 studies: Study 

















▪ Many IPED users 






▪ Most products 




Not Discussed Harm reduction 




poor quality and 
dangers of 
substances 










the eye of a 
needle” - An online 
study of the 
practices and 










Van Hout, M.C. 
. 
AIM: To explore 
and describe 
experiences, 
beliefs and values 








▪ People who 
inject IPEDs often 
educate 
themselves on 






was reported as a 
solution to high 
blood pressure 
and excess red 
blood cells.  
▪ Needle fixation 
and  
injecting pleasure 
was identified and 














safety and health 









HCPs are advised 




























Licit forms of 
performance 




doping in sport 
and exercise 
 ▪ The review 
suggests that the 
positive link 
between licit and 









policies to limit 
Practitioners 
could present 






use of licit and 








possible links with 











(GHDSE) and the 
incremental 











using illicit forms. 
METHOD: Review 
▪ The reliance on 
cross-sectional 
designs to date 





currently be made. 





A ‘food first’ 
approach to 
divert athletes 




over time, and 












use: It’s not all 







Backhouse, S. METHOD: Review  ▪ A ‘one size fits 
all’ approach will 
not be successful 
in either sport or 
public health 
environments. 







IPED use and the 
lives of those who 
use them.  





not supported is a 
concern as their 




Delivery of an 
integrated range 
of interventions 




to and prevalence 
of IPED use are 
needed.  
The complex 




























people who use 
anabolic 
androgenic 








Van Hout, M. 
C. 
Teck, J. T. W. 
McVeigh, J. 
AIM: To identify 
and describe what 
is known about 
interventions that 
aim to support 
and achieve 
cessation of AAS 






AAS users ▪ Evidence on 
interventions to 
support cessation 




▪ Evidence of 
engagement with 
















in users is scarce. 




















AIM: To examine 
intervention 
effectiveness of 
 ▪ Using the EPHPP 
tool three studies 
were rated strong, 
five studies were 
rated moderate, 
- Not Discussed Suitable 
interventions are 
required that 
To establish the 











prevent misuse of 














and nine studies 
were rated weak.  
▪ Evidence on how 
to reduce use of 
AAS is scarce. 
There is a need to 
respond to the 
different issues of 
the use of AAS 




▪ Strategies to 
tackle AAS use will 

















this area, a 
more consistent 
and rigorous 
approach to the 
development 












prevention in the 















fitness doping can 
be understood in 
relation to, and 
how it is affected 
by, different 






from Sweden and 
United States. 
 ▪ Two themes 
emerged: 
Individual freedom 
and doping in the 
U.S; and Fitness 










▪ The U.S. does 
not police outside 
formally governed 
competitions in 
sports or in 
criminal contexts.  
▪ U.S. 
bodybuilders do 
not feel targeted 
for their 





The gap between 
the global and the 





doping needs to 




























typology of men 













AIM: To identify 
typologies of 
people who use 
AAS and examine 
variations in 
motivations for 




at NSPs and 
Online Fora 
611 men who 
use AAS 
▪ Study developed 
a quantitative 
typology of AAS 
users. 
▪ Four types: 
YOLO, Wellbeing, 
Expert and Athlete 
types. 
▪ YOLO type is 
young, 
inexperienced, 
with high levels of 
risk; Wellbeing 




risky; Athlete type 
were more likely 
to be older, use of 
Not Discussed Harm 
minimisation 
services are 








disposal sites are 
accessible. 
Further analyses 
of routine data 













AAS and other 
IPEDs; Expert type 
minimal AAS and 














Google Trends.  
 
MRC/CSO Social 





McCann, M. AIM: To assess 










 ▪ A clear and 
consistent 
seasonal variation 





▪ From April to 
July (bulimic 
seasonality) peaks 
of search interest 
were noted. 
▪ The study may 
support the idea 
that AAS use is 























services may be 

































91 Mitchell St, 
Glasgow G1 3LN 
 AIM: To capture 
our current 
understanding of 






Scotland to date. 
METHOD: Review 
 Four Issues 
Identified: 
1. A lack of data 
and research 
2. Need for 
specialist IPED 
Provision 
3. Need for Links 
to health services 
and 
endocrinology. 
4. The role of gyms 
– need to be 
viewed as good 







drug policy and 
responses under 
the Sexual Health 
and Blood Borne 
Viruses 
frameworks. 




demand for a 
specialist IPED 





ensure that there 
is an appropriate 
level of 
knowledge of 














around IPED use 
to provide 

























‘Shades of Grey’: 
The Ethics of Social 
N/A AIM: To reflect on 





 ▪ Most people 
who use AAS are 
not vulnerable 
because of their 
use. 
▪ Health risks may 
increase if one 
become 
Not Discussed Social work 
practitioners 
should be able to 
understand the 
motivations for 































▪ No evidence that 
individuals are 
unable to manage 
daily living whilst 
using AAS. 
▪ Social workers 
should be aware 
some groups of 
people who are 
more at risk to 
starting AAS use. 
they discuss the 
associated risks.  
 
and support to 
help people 








A qualitative study 
of the motivations 
for anabolic-
androgenic steroid 








University of Wales 


























▪ MD Symptoms 
developed in some 
because of them 
feeling ‘physically 
inferior’ to others. 
▪ The primary 
motivator for use 
among those who 
began using AAS in 




▪ Frustration with 
training (and a 
drive for 
muscularity) was 
the motivation for 
those who started 
using in their late 
20s,  
▪ Inability to cease 
AAS use was due 
to fear of losing 
gains; 
psychological 
addiction to the 
way AAS made 
them feel; and 
age-related 
benefits to stave 
off ageing. 
Future initiatives 
will need to focus 




and improve social 














may wish to 
assist those who 
depend on the 
positive effects 
of AAS to explore 
alternative 







going into gyms 











age at which 









MD post AAS 












Drug Use in Society 
and the Impact on 
the Anti-Doping 
Movement.  
McVeigh, J. AIM: To examine 




 ▪ The issue of 







▪ Athletes and the 
wider society may 
use drugs for a 
wide variety of 




debate the issues 
relating to 







Faculty of Science, 

















the demand for 
and acceptance of 
enhancement 
technologies 
PIED use within 
the context of 
societal drug use. 





















Wells, J. S. G. 




explore how a 
practice such as 
self-phlebotomy 
may become 













▪ Motivation to 
‘self-bleed’ were 
grounded in a high 
red blood cell 
count or 
(perceived) 
symptoms of high 
blood pressure. 
▪ No harms were 







is needed in this 






















“Raw juicing” – an 
















Wells, J. S. G. 
Van Hout, M.C. 
. 














grounded in the 
circumventing of 
unreliable online 








▪ The potential for 






areas of concern. 







research in this 
field, especially 
























relevant to doping 


















doping in sport 
and exercise and 
provide evidence 
for the validity 






 ▪ Three 
psychometric 
instruments 




▪ Factor analyses 
identified the final 
items and 
dimensional 










Scale (DSRES).  
▪ The DMDS has 6 
lower- and 1 
higher-order 
factors. 
▪ The DMDS-S and 
DSRES are 
unidimensional. 
▪ These structures 
were invariant by 
sport/exercise 
context and sex.  
▪ Evidence was 
also provided to 









developed for use 
with both sport 
and exercise 
populations. 






























AIM: To discuss 
the different 
influences on AAS 
use and how 
these influences 
interact to effect 
decision-making 
in one framework. 
METHOD: Review  
AAS users ▪ Socioecological 
framework 
suggests that the 
interaction of 





societal levels that 
are likely to 
change over time 
influences the use 
of AAS. 





that are influential 
for different 
groups will result 
in an increased 
understanding of 
AAS use.   
An increased 
understanding of 















































University, L16 9JD 
Liverpool, UK. 




George, K. P. 
AIM: To assess 
cardiac function 
and biomarker 




exercise session in 
age matched AS 

















▪ A reduction in 
several indices of 
diastolic function 
(E’, E’: A’ and E: A) 
post-exercise was 







produced by an 
acute bout of 
resistance 
exercise. 
▪ There was no 
significant effect 
of exerciser AS use 
on E: E’. 
▪ Changes to 
diastolic driving 





Not Discussed An increase in 
the number of 
post-exercise 














further help the 
understanding 









Being in control? A 
thematic content 
analysis of 14 in-
depth interviews 
with 2,4-






Surrey, KT1 2EE, 
UK. 
Vargo, E. J. 
Petroczi, A. 
AIM: To explore 
2,4-DNP users’ 
attitudes towards 





their 2,4-DNP use, 











DNP users on 
bodybuilding 
forums. 
▪ The element of 
control over every 
aspect of the 
users’ life appears 
to be a key 










relations with the 







































in gyms and 
other online 
platforms of 
2,4-DNP use is 
warranted. 
⚫ 






















related to service 
satisfaction 
among AAS users. 
METHOD: 
Retrospective 
AAS Users ▪ 35% reported 
seeking advice 
from GP due to 
AAS related 
adverse effects 
with the majority 
reluctant to do so. 
▪ Sexual function 
issues were a 
driver for men to 
seek GP 
treatment. 
▪ Those AAS user 
that did seek GP 
and medical 
advice were in the 
older age group. 
The incidence and 









health care must 




the use of AAS. 
 
The benefits of 








Institute for Social 
Science Research, 





data analysis of 
the GDS 








▪ Hepatitis B/C 
and HIV screening 
were associated 



















investigation in the 













AIM: To explore 














 ▪ Males were the 
majority of those 
who reported 
product use to 
achieve their 
fitness goals.  
▪ Females were 
more inclined to 
use weight loss 
products. 
▪ Experience side 
effects was not 









occur in the 
presence of 
physical illness 












false or misleading 
advertising is 
warranted. 
Not Discussed Further 
investigation of 










































 ▪ The implications 
of the rise in IPED 
use in the UK and 
Scotland, 
particularly in 
relation to the 
prevalence of 
BBVs amongst 
IPED users is a 
public health 
concern. 















of a formal 
Scottish strategy 








in Scotland should 















training for GPs 





service for IPED 
users and to 
bridge the gap 
that exists 
▪ A Scotland-






including use in 
prison. 
▪ Information 
on the market 
including drug 
composition.  
and the role of 





























the inferno drug: a 
netnographic 
study of user 
experiences in the 








Van Hout, M. 
C. 
AIM: To explore 





















were discussed.  
▪ The efficacy and 








bodybuilders only.  
▪ Descriptions of 
dosage and 
regimes for 




and surveillance of 


















needed to reach 









in the UK: an 
increasing issue for 







Begley, E. AIM: To identify 




use in the UK to 
better understand 








and review of the 
evidence related 








increase in the 
number of AAS 
users accessing 
NSPs to become 
the main client 
group. 
▪ Increased mean 
age of steroid 
using clients from  
With the 
identification of 
HIV in the 
population and 
signs of rising 
prevalence, public 







a robust harm 
reduction 
strategy. 




the context of 
increasing 






outreach to gyms 
and other 
environments 
where AAS use is 
likely to be found 
are needed.  
Future research 
to estimate the 
scale, patterns, 
and drivers of 
AAS use. 
 
The nature of 
the illicit market 
and the position 


















among people who 























▪ One in 20 of 
those injecting 
IPEDs sampled had 
anti-HCV. 
▪ One in 70 of 
those injecting 
only IPEDs had 
antibodies. 
▪ Of those who 
injected IPEDs 
only, who had 
been infected with 
hepatitis C were 








hepatitis C testing 
among people 






























▪ The minority 
who had injected 
both IPEDs and 
psychoactive drugs 
had a higher 
hepatitis C 
prevalence and 
higher uptake of 
testing than those 
who had just used 
IPEDs 
need to be is 
needed. 

















CF5 2YB, UK. 
Dunn, M. 
Alwyn, T. 
AIM: To examine 
the extent to 
which users and 
non-users of AAS 
differ in levels of 
intrasexual 
competition, to 




users with varying 
usage experience 
and to investigate 












▪ A statistically 
significant 
difference in levels 
of intrasexual 
competition 
between users and 













competition in the 
novice group. 
▪ AAS users exhibit 


















Not Discussed Not Discussed Future research 








focusing on the 
usage of these 
life-threatening 
substances 





















accounts of use. 
 
School of Law, 
Criminology and 
Government, 
Coomber, R. AIM: To examine 
steroid user 
motivations, 
patterns of use, 













▪ Steroid use 
patterns varied 
according to 
motivation for use, 
experience, and 
knowledge gained. 
▪ Most gained 
information from 
fellow users or 
suppliers. 
▪ Many users 
differentiated 
themselves from 





patterns of use of 
younger and (what 




drug policies can 
be developed by 
examining the 
social contexts of 
steroid use and 
the social and 
cultural meanings 
individuals attach 











users and the 
specific local and 
wider contexts of 







contexts of use 
and user beliefs 
and motivations 































policies, such as 
regulation. 
 








the illicit medicine 





School of Social 
Sciences, Business 









Analysis of both 
on Data analysis 






 Study 1 UK: 
▪ to explore and 
examine the size, 
scope, nature, and 
dynamics of the 
illicit medicine 
market in the UK, 













the trade in illicit 




Main Findings of 
the current study: 















▪ The UK serves as 
a transit country 
and the 
Netherlands, as a 
transit country, is 
also increasingly 
used as a 
manufacturing 
hub. 
Not Discussed Not Discussed Not Discussed 
⚫ 









 ▪ Information 
about new drugs 






evaluation of the 
new legislative 
landscapes that 
are developing as 



















University of Kent, 
United Kingdom. 
drugs is urgently 
needed.  
▪ An improved 
evidence base for 
policymakers and 
practitioners to 








a direct result of 
rising anxieties 






evidence of harm 















such as the 
prison 
population and 

















The injecting use 
of image and 
performance-
enhancing drugs 













Van Hout, M.C. 
 
AIM: To review 
the injecting use 
of image and 
performance-
enhancing drugs 







▪ Motivations for 
the use of IPEDs 
are grounded in 
appearance, 
pursuit of health 
and youth, and 
body image 
disturbance. 
▪ Moderated use 
was reported. 











pathways of use. 













health and social 








































Smith, A. L. 
Mills, J. P. 
Grix, J. 
Wynne, C. 
AIM: To test a 









▪ The efficacy of a 







▪ Empathy and 
doping SRE 
negatively 
Not Discussed Not Discussed Research that 



























▪ The predictive 
effects of empathy 
and doping SRE on 
reported doping 
were mediated by 
doping MD and 
anticipated guilt. 




▪ The predictive 
effects of doping 






testing aspects of 
the project were 
based on cross-
sectional data; the 
causal nature of 
the predictive 
effects identified 
could not be 
tested and 
therefore should 
not be inferred. 
the causal 









proposed in the 




































AIM: To explore 
image and 
performance drug 




at gyms and NSPs.  
IPED Users ▪ AAS most 
reported IPED 
used –  
▪ 89% ever used 
oral IPEDs, 85% 
ever injected.  
▪ More than half 
would not seek 
medical advice for 
an adverse effect 
of use.  




and practice is 
challenging as 
people using 
IPEDs report the 
use of a broad 












needs of IPED 
































Bates, G.  
 
2017 
HIV among people 
using anabolic 
steroids in the 
Hope, V. D. 
McVeigh, J. 
AIM: To discuss 
anabolic steroid 
use in the context 
of HIV 
METHOD: Review 
 ▪ Increasing 
awareness and an 
understanding of 
the characteristics 
and risks of people 




Not Discussed Health 
professionals aim 





















▪ HIV testing 
should be offered 
to people using 
AAS presenting at 
healthcare 









▪ It is essential 







stigma and the 
potential for 
further barriers to 
engagement. 
infections among 
all people who 
use drugs 
including those 







offer testing and 
treatment for 








Nurses and other 
healthcare 
professionals can 






HIV testing, and 
increasing their 
awareness of 
AAS use and 
associated risks 
will support this. 
those who use 












services by this 
population 





Female Use of the 
Synthetic Growth 
Hormone CJC-





Health, Sport and 
Exercise Science, 




AIM: To explore 
female use of CJC-
1295, a synthetic 
growth hormone 







IPED Users in 
online fora 
▪ Forum users 
were well versed 
and experienced in 
the poly use of 
IPEDs. 
▪ Choice to use 
CJC-1295 centred 





and injury healing. 












































































METHOD: Review  ▪ The authors 
argue that body 
image 
dissatisfaction 
should be a 
concern to all 
those interested in 
mental health. 
▪ Simple messages 
that the use of 
AAS can damage 
long-term health 
are unlikely on 
their own to be 
effective in this 
population. 
 
Not Discussed Care must be 
taken with those 
who have ceased 
AAS use to 
encourage them 
to develop other 
interests that 
may at least 
reduce their 
reliance on their 












levels that result 
from cycling off 
AAS, suicidal 
ideation can 






of MD with 
former AAS 
users to see if 
they self-
identify times in 
their lives when 
they behaved in 
such ways and 
suffered from 































Hope, V. D. 
METHOD: Letter N/A ▪ The authors 
support the role of 
harm reduction in 
the “fight” against 
HIV,1. 
▪ The authors 
broadly agree with 
the findings of the 
report “The Case 





▪ IPED users are a 
growing client 




needle and syringe 
programmes. 
▪ HIV prevalence 
of 1.5% in men 
The use of IPEDs, 
particularly the 
injection of AAS by 
men, must be 





























who inject IPEDs 
reported. 


































 ▪ A traditional 
understanding of 
AAS use as 
substance abuse 





which places AAS 
use within a larger 
disorder such as 
OCD or an eating 
disorder. 
▪ The largest body 
of literature to 
date suggests 
placing AAS use 
within either the 
category of an 
eating disorder or 
BDD. 
▪ Many similarities 
between the 
psychological 
profile of AAS 
users (mostly 
male) and anorexic 
patients (mostly 
female. 
▪ A major finding 
from this review is 
that the number of 
steroid users 
taking part in the 
included studies is 
very low 
compared to the 
number of users. 
  Future research 
to understand 
ASS use is 
recommended 
to influences 





















Access to needle 
and syringe 
programs by 




















funding of harm 
reduction 




Beek & Chronister, 
2015). 
▪ The authors 







provision for all 
people who inject 
drugs. 
Consideration of 
the potential for 
all types of 
injecting drug use 
to increase the 
risk of 
transmission of 
BBVs and cause 




identify ‘need’ of 
specific groups of 
people who 
inject drugs, in 
which those 
injecting IPEDs 
are deemed to 
be at negligible 
risk of BBV 
transmission, 
may result in 
increased 
complacency and 












Risk of HIV and 
Hepatitis B and C 
Over Time Among 
Men Who Inject 
Harris, R. 
McVeigh, J. 
Cullen, K. J. 
Smith, J. 











 ▪ BBV infections 
are a problem 
among people 
who inject IPEDs. 
▪ There is an 
overlap of BBV 
infections with the 
MSM population. 






reduce risks are 
indicated. 
 
There is a need 
for targeted 
interventions to 



























▪ HIV prevalence is 




▪ Both sexual and 




injecting IPEDs.  
address sexual 
health and drug 
use risks among 
those injecting 
IPEDs. 































steroid (AAS) use 
by young men, 

















AAS use was 
identified. 
▪ A transitional 
period whereby 
AAS use, and 
bodybuilding 
fuelled the 
expression of a 
body image 
problem, rather 
than a body image 
problem 
precipitating AAS 
use was identified. 




into a problematic 
pattern of body 
image concerns. 
▪ A pattern of 
problem 
behaviours to be 
highly prominent 
during the 
initiation of AAS 
use was revealed. 
 A more complex 
relationship 
between body 






those in practice 
and healthcare. 
Future research 
into the extent 















synthol use: The 












▪ Study provided 





experts in this 
discussion group.  
▪ Users clearly 
expect that 
synthol will give 
them a natural, 
trained look and 
are keen for 
advice on how to 
use synthol and 
get good results 
while minimising 
unwanted side 
effects such as 
pain and unsightly 
bumps. 
▪ People with 
practical 







users to have 
somewhere to 
go to find 
accurate 
information on 
health risks and 






experience of use 
are treated with 
respect and 




is factual and 
generalisable 
beyond personal 
experience of use. 




Fake Meds Online 
the Internet and 
the Transnational 









AIM: To provide 




of the online 









 ▪ This book 
provides a timely 
criminological 
investigation into 
the sale of fake 
medicines online. 
Chapters focus on: 
1. The Online 
Trade in Illicit 
Pharmaceuticals: 
The UK Context 
2. The Demand 
Side 
3. The Supply Side 
Policymakers need 
to consider that 








that blur the 
boundaries of 
legality. 











or in high doses, 




















Baker, J. S. 
Davies, B. 
METHOD: Review  All drugs or 
medicines have 
side effects, which 
are exacerbated if 
the dosages taken 
are excessive.  













respect to UK 
legislation 
 More research 
















cognitions in men: 











(NT), and drive for 
muscularity (DFM) 









▪ DFM significantly 
predicted 
weightlifting, 










▪ The interactions 
between NT and 
DFM and NT and 
internalization 
predicted MD. 
Not discussed When 
muscularity-
focused issues 












to explore the 


















Institute of Sports 









not be effective. 






















low energy.  
▪ History of high-
dose AAS use for 
7-8 years; ceased 
use 3 years 
previously. 
▪ Test revealed 
mildly raised BMI 
of 28. 
▪ Low total 
testosterone. 





citrate, 50mg on 
alternate days.  
▪ 3 months later, 
total, and free 
testosterone levels 
had increased a 
little. 
▪ May indicate 
that duration of 
the hypogonadal 
symptoms greater 
in those who use 
higher doses, and 
for a longer time, 
and older men. 
  Future research 
should focus on 
exploring 


































substance use in 















▪ 91.9% of the 











▪ Prevalence of 
PED use was low. 








supports a need to 
control the use of 
some substances 
in dance, 
attention must be 





doping policy in 
sport.  
Consideration for 
dancers and how 


































season may be 
beneficial.  















McVeigh, J. AIM: To explore 
image and 
performance drug 






IPED Users ▪ Study focused on 
all IPEDs. Majority 









▪ Reasons to use 




and fat loss. 
▪ IPED using 
populations, 
practices and 
health risks are 
ever changing with 
a dynamic fast-
paced market. 






users with health 









to improve blood 
borne virus 









































Hall, A. AIM: To provide 





business in the 
UK. 
METHOD: Review. 













and offline, and 
for both use and 
supply. 




















Figure 1 Flow chart of the search strategy used to identify image & performance enhancing drug 





















0 5 10 15 20 25 30 35 40 45
Gender, body image, exercise etc
Non- AAS drugs eg weight loss drugs
Public health, treatment &harm reduction
Policy/legislation
Sports & doping control*
Illicit market & adulteration
Psychological harms
Blood borne viruses
Physical harms (excluding BBV)
Epidemiology, sub groups & motives
2016 (15) 2017 (14) 2018 (12) 2019 (29) 2020 (17)
